牟平站 |  “石药集团烟台生物医药高科技产业园”项目：集创新药物研发、生产和销售于一体

　　Yantai Bio-medicine Hi-tech Industrial Park of CSPC in Muping: An Integration of R&D, Production and Sales of New Drugs

　　该项目总投资30亿元，占地500亩，是石药集团在山东唯一的集创新药物研发、生产和销售于一体的高科技生物医药项目。主要有三个特点：

　　The project has a total investment of 3 billion RMB, occupying 500 acres. As the only hi-tech bio-medicine project that integrates R&D, production as well as sales of new drugs in Shandong Province, it owns three dominating features.

　　一是发展势头猛。石药集团百克(山东)生物制药有限公司于2010年落户牟平，2013年底一期建成投产。投产初期年销售收入1000万元、纳税不足200万元，到2016年销售收入首次突破1亿元、纳税突破1000万元，2022年销售收入超过25亿元、纳税达到2.3亿元，7年增长了25倍。2023年1月纳税4300万元，同比增长26%，预计全年纳税2.5亿元。

　　The first feature is its dashing momentum for development. CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd. headquartered itself in Muping in 2010 and accomplished its first-phase project in 2013. At first, its annual sales revenue was about 10 million RMB with only 2 million taxation. While by the time of 2016, the number reached 100 million RMB for the first time with over 10 million RMB taxation. In 2022, the annual sales revenue exceeded 2.5 billion RMB with taxation of 230 million RMB 25 times within seven years. In January 2023, the company payed taxes of 43 million RMB, a 26% year-on-year increase. A 250-million tax is expected for the entire 2023.

　　二是科技含量高。主打产品“津优力”，是国家一类新药，列入国家重大新药创制专项，在非髓性恶性肿瘤治疗方面具有显著疗效，2017年获得中国国家专利金奖，2021年获国家科技进步二等奖。

　　The second feature is the high technology applied to its products, featuring Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) for Injection. It is a new state first-class drug and has been admitted by China's Significant New Drug Development Project. The drug delivers outstanding treatment effects for Non-myeloid malignancies, thus winning the gold medal of China Intellectual Property Award and second prize of the State Preeminent Science and Technology Award.

　　三是成长潜力足。2019年，公司瞄准国际化发展目标，启动产业园二期建设，目前，津优力300万只扩产项目顺利达产，JMT103和TG103两个国家一类新药即将上市投产，达产后预计增加产值20亿元、税收2亿元。随着研发投入超过20亿元的7个国家一类新药陆续落户上市，该项目将打造成为石药集团全国最大的生物医药产业化基地。

　　The third one is its great potential for growth. In 2019, the company set a goal of going more globalized by initiating its second-phase construction. Currently, the program to expand production capacity to 3 million pieces of the PEG-rhG-CSF has been accomplished. Two new state first-class drugs, JMT103 and TG103, will be put into production with an estimated 2 billion RMB sales revenue and 200 million RMB taxes added. Following these moves, 7 more new state first-class drugs with an investment of over 2 billion RMB R&D funds will go to market successively, making the new project CSPC’s biggest bio-medicine industry base within China.